Cargando…

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

INTRODUCTION: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domingues, Gerson, Chinzon, Decio, Moraes-Filho, Joaquim Prado P., Senra, Juliana Tosta, Perrotti, Marcos, Zaterka, Schlioma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050988/ https://www.ncbi.nlm.nih.gov/pubmed/37007753 http://dx.doi.org/10.5114/pg.2022.116673

Ejemplares similares

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review
por: Chinzon, Décio, et al.
Publicado: (2021)

Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data
por: Moraes-Filho, Joaquim Prado P., et al.
Publicado: (2022)

Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Gastric polyps' regression after potassium‐competitive acid blocker cessation
por: Iwamuro, Masaya, et al.
Publicado: (2022)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
por: Mori, Hideki, et al.
Publicado: (2019)

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
por: Oshima, Tadayuki, et al.
Publicado: (2018)

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report
por: Shao, Yuyang, et al.
Publicado: (2022)

Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication
por: Eisig, Jaime N, et al.
Publicado: (2009)

Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
por: Hunt, Richard H, et al.
Publicado: (2015)

Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
por: Okamoto, Masaru, et al.
Publicado: (2021)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
por: Ku, Jin Mo, et al.
Publicado: (2023)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Comorbidities are Frequent in Patients with Gastroesophageal Reflux Disease in a Tertiary Health Care Hospital
por: Moraes-Filho, Joaquim Prado P, et al.
Publicado: (2009)

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept
por: Wang, Ming-Shu, et al.
Publicado: (2022)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

INFLUENCE OF EXERCISE TESTING IN GASTROESOPHAGEAL REFLUX IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
por: MENDES-FILHO, Antonio Moreira, et al.
Publicado: (2014)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan
por: Habu, Yasuki, et al.
Publicado: (2021)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
por: Kim, Ji Yeon, et al.
Publicado: (2021)

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
por: Zhou, Sufeng, et al.
Publicado: (2023)

Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study
por: Navarro-Rodriguez, Tomás, et al.
Publicado: (2013)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia
por: Asaoka, Daisuke, et al.
Publicado: (2017)

Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Prediction of effectiveness of potassium-competitive acid blocker and serotonin noradrenaline reuptake inhibitor on abnormal sensation in the throat: use of patient-reported outcome measures (PROMs)
por: Takahashi, Nao, et al.
Publicado: (2021)

Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial
por: Eisig, Jaime Natan, et al.
Publicado: (2015)

Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials
por: Zhang, Mengran, et al.
Publicado: (2022)

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study
por: Kim, Min-Gul, et al.
Publicado: (2023)

Fatty Acid and Related Potassium Kv2 Channel Blockers: Toxicity and Physiological Actions on Mosquitoes
por: Démares, Fabien, et al.
Publicado: (2018)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g0hicl3rqdje7scqq8tj9bs7cd